Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 0.90 |
| ▸ | GRM6 | O15303 | 2/20 | 0.90 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.90 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.90 |
| ▸ | GSR | P00390 | 2/20 | 0.90 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.90 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.90 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.90 |
| ▸ | GRM5 | P41594 | 1/20 | 0.90 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.90 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.90 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.90 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.90 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.90 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.90 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.90 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.90 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.90 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Glutamate SCHEMBL563907 | 1.00 | GRM8 (0.90) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL4261783 | 1.00 | GRM8 (0.90) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL4261779 | 1.00 | GRM8 (0.90) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL21930645 | 0.98 | GRM8 (0.86) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL9534869 | 0.98 | GRM8 (0.86) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL8649393 | 0.95 | GRM8 (0.90) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL8648787 | 0.95 | GRM8 (0.90) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL17127348 | 0.95 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL1330484 | 0.95 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL248800 | 0.95 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001891-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | KEYMED BIOSCIENCES (CHENGDU) CO., LTD. (CN) | 2026-01-01 | — | — | US | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4623936-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | Keymed Biosciences (Chengdu) Co., Ltd. (CN) | 2025-10-01 | — | — | EP | claimed |
| EP-4600271-A2 | BIOACTIVE MOLECULE CONJUGATE, PREPARATION METHOD AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-13 | — | — | EP | claimed |
| EP-4594492-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| WO-2025040012-A1 | PENTACYCLIC ACTIVE COMPOUND AND CONJUGATE THEREOF AND USE THEREOF | 康诺亚生物医药科技（成都）有限公司 | 2025-02-27 | — | — | WO | claimed |
| WO-2025035608-A1 | GLUTAMIC ACID UREA COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF, NUCLIDE TARGETING PROBE AND PREPARATION METHOD THEREFOR AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION | 厦门大学 | 2025-02-20 | — | — | WO | claimed |
| WO-2024239281-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| US-20240368583-A1 | DNA CONSTRUCTS, RECOMBINANT CELLS COMPRISING THEREOF, BACTERIAL PROBES, METHODS FOR THEIR PREPARATION, AND METHOD OF USING THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-11-07 | — | — | US | claimed |
| WO-2024109840-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | 康诺亚生物医药科技（成都）有限公司 | 2024-05-30 | — | — | WO | claimed |
| US-20230159611-A1 | SMALL MOLECULE ADAPTER REGULATED, TARGET SPECIFIC CHIMERIC ANTIGEN RECEPTOR BEARING T CELLS (SMART CARS) | YALE UNIVERSITY | 2023-05-25 | — | — | US | claimed |
| US-20210101906-A2 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-04-08 | — | — | US | claimed |
| WO-2020252203-A1 | DEODORANT COMPOSITIONS | G&S Laboratories, Inc. (US) | 2020-12-17 | — | — | WO | claimed |
| US-20200347075-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-11-05 | — | — | US | claimed |
| EP-3725798-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-10-21 | — | — | EP | claimed |
| WO-2020031136-A1 | THERANOSTICS-LIKE PROTEIN SANPS CONJUGATED TO INTEGRIN AND PMSA TARGETING PEPTIDES AND THERAPY OF PROSTATE CANCER | INTEGRATIVE MEDICINE CLINIC, SIA (LV) | 2020-02-13 | — | — | WO | claimed |
| WO-2020030954-A1 | THERANOSTICS-LIKE PROTEIN SANPS CONJUGATED TO INTEGRIN AND PMSA TARGETING PEPTIDES AND THERAPY OF PROSTATE CANCER | INTEGRATIVE MEDICINE CLINIC, SIA (LV) | 2020-02-13 | — | — | WO | claimed |
| WO-2019154120-A1 | CYTOTOXIC AGENT AND CONJUGATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2019-08-15 | — | — | WO | claimed |
| WO-2019149116-A1 | METHOD FOR PREPARING CONJUGATE | 四川科伦博泰生物医药股份有限公司 | 2019-08-08 | — | — | WO | claimed |
| US-20130317196-A1 | TRIAZANONANE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR ENHANCED FLUORINE-18 LABELING | SNU R&DB FOUNDATION (KR) | 2013-11-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317196-A1 | TRIAZANONANE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR ENHANCED FLUORINE-18 LABELING | SLC10A1, SLCO1B1, SLCO1B3 | GRM8 1159/4885GRM6 3023/4885GRM7 2490/4885 |
| US-20230159611-A1 | SMALL MOLECULE ADAPTER REGULATED, TARGET SPECIFIC CHIMERIC ANTIGEN RECEPTOR BEARING T CELLS (SMART CARS) | CD47, CD4, CD2 | GRM8 796/4885GRM6 870/4885GRM7 1764/4885 |
| US-20200347075-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | DOCK11, PAICS, RHOA | GRM8 1827/4885GRM6 3079/4885GRM7 2524/4885 |
| US-20210101906-A2 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | DOCK11, PAICS, RHOA | GRM8 1827/4885GRM6 3079/4885GRM7 2524/4885 |
| US-20260001891-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | HCCS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1 | GRM8 2571/4885GRM6 1935/4885GRM7 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.